Mallinckrodt PLC Forecasted to Post Q1 2018 Earnings of $1.39 Per Share (MNK)
Mallinckrodt PLC (NYSE:MNK) – Research analysts at Leerink Swann issued their Q1 2018 earnings estimates for Mallinckrodt in a note issued to investors on Tuesday. Leerink Swann analyst A. Fadia expects that the company will post earnings per share of $1.39 for the quarter. Leerink Swann has a “Market Perform” rating and a $26.00 price target on the stock. Leerink Swann also issued estimates for Mallinckrodt’s Q2 2018 earnings at $1.79 EPS, Q3 2018 earnings at $1.99 EPS, Q4 2018 earnings at $2.03 EPS and FY2022 earnings at $7.18 EPS.
Mallinckrodt (NYSE:MNK) last issued its quarterly earnings data on Tuesday, November 7th. The company reported $1.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.17. Mallinckrodt had a net margin of 11.43% and a return on equity of 14.79%. The firm had revenue of $793.90 million for the quarter, compared to the consensus estimate of $808.93 million. During the same quarter in the previous year, the firm earned $2.04 EPS. The company’s quarterly revenue was down 10.5% compared to the same quarter last year.
Shares of Mallinckrodt (MNK) traded up $0.20 during trading on Thursday, hitting $23.71. 602,780 shares of the stock were exchanged, compared to its average volume of 2,906,400. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.05 and a current ratio of 1.38. Mallinckrodt has a 52-week low of $19.00 and a 52-week high of $55.32. The stock has a market cap of $2,230.00, a P/E ratio of -1,185.50, a P/E/G ratio of 0.45 and a beta of 1.30.
A number of hedge funds and other institutional investors have recently made changes to their positions in MNK. Sterling Capital Management LLC acquired a new stake in Mallinckrodt during the 2nd quarter valued at approximately $204,000. Shelton Capital Management acquired a new position in shares of Mallinckrodt in the 3rd quarter valued at $205,000. Cubist Systematic Strategies LLC lifted its stake in shares of Mallinckrodt by 748.1% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 7,989 shares of the company’s stock valued at $299,000 after purchasing an additional 7,047 shares during the period. Pinnacle Associates Ltd. lifted its stake in shares of Mallinckrodt by 69.8% in the 3rd quarter. Pinnacle Associates Ltd. now owns 8,025 shares of the company’s stock valued at $300,000 after purchasing an additional 3,300 shares during the period. Finally, Meiji Yasuda Asset Management Co Ltd. acquired a new position in shares of Mallinckrodt in the 3rd quarter valued at $305,000. Institutional investors and hedge funds own 97.35% of the company’s stock.
In other Mallinckrodt news, CEO Mark Trudeau acquired 5,000 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was acquired at an average cost of $22.28 per share, for a total transaction of $111,400.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Dr Kneeland Youngblood acquired 4,560 shares of the firm’s stock in a transaction on Tuesday, November 28th. The shares were acquired at an average price of $21.94 per share, with a total value of $100,046.40. Following the completion of the purchase, the director now owns 19,789 shares in the company, valued at approximately $434,170.66. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 30,460 shares of company stock worth $659,486. 0.77% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/04/mallinckrodt-plc-forecasted-to-post-q1-2018-earnings-of-1-39-per-share-mnk.html.
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.